10月26日,哥伦比亚大学团队发表在《Molecular Cell》上的研究证实,淀粉样纤维可作为RNA的护送者,精液依赖淀粉样纤维将遗传物质直接输送至精子细胞内,从而影响下一代的表观遗传学特征,揭开了父系表观遗传信息如何从精浆进入成熟精子的长期谜团。在神经生物学领域,淀粉样蛋白通常被认为是阿尔茨海默病、帕金森病等神经退变性疾病的病理学标志,其聚集形成的神经毒性斑块和纤维会破坏突触。然而,这项研究表明,功能性淀粉样蛋白在人体内承担着非病理学的生理功能。
10 月 28 日,哈佛医学院和波士顿儿童医院团队在《Nature》上发表研究论文,揭示了胎儿四分之一的神经元DNA严重异常,存在多种拷贝数变异,而这些异常的神经元会在出生前后(围产期)被选择性清除,因为这些神经元的拷贝数变异破坏了神经元的突触形成能力。这种机制代表了大脑发育过程中一种重要的神经元基因组质量控制过程,提示了人类神经发育过程中存在净化选择。若该过程存在缺陷,可能导致神经发育疾病。
10月28日,丹麦生物科技公司Genmab公布,在一线治疗PD-L1阳性复发/转移性头颈癌患者的3期临床试验中,首次期中分析显示,采用Petosemtamab(一种全人源IgG1双特异性抗体,靶向表达表皮生长因子受体和富含亮氨酸重复序列的G蛋白偶联受体5的肿瘤细胞)联合治疗可带来具有统计学显著性和临床意义的总生存期及客观缓解改善。结果显示,与单用帕博利珠单抗相比,采用Petosemtamab联合帕博利珠单抗治疗可使死亡风险降低50%;联合治疗组获得客观缓解的概率是对照组的3倍以上;而且,无论人乳头瘤病毒状态如何,均观察到了疗效的改善。头颈部鳞状细胞癌是一组生物学特征相似的癌症,起源于口腔、咽部和喉部表面的衬里组织;占所有头颈部癌症的90%以上,尽管目前已有多种治疗手段,但患者对新疗法的需求依然迫切,约50%的局部晚期头颈部鳞状细胞癌患者在接受初步治疗后会出现疾病复发。
10月29日,中国科学院分子细胞科学卓越创新中心、长海医院、上海市第一人民医院、重庆医科大学联合团队在《Cancer Cell》发表研究成果,基于大规模胰腺癌患者来源类器官生物样本库,结合多组学分析、功能筛选及体内实验,系统描绘了胰腺癌对 KRASG12D 靶向治疗先天耐药的分子特征,发现干扰素信号通路活性是影响治疗敏感性的重要因素,并进一步揭示了 MYC 活性增强与干扰素信号受抑及 KRAS 靶向耐药之间的关联。他们发现,干扰素β能够增强先天耐药胰腺癌类器官对 KRAS 抑制剂的敏感性,为克服胰腺癌 KRAS 靶向治疗耐药及探索合理联合治疗策略提供了新思路。
Global Biomedicine Highlights, October 25–31, 2026
On October 26, a team from Columbia University published findings in Molecular Cell confirming that amyloid fibers can serve as carriers for RNA. Seminal fluid relies on these amyloid fibers to deliver genetic material directly into sperm cells, which can then shape epigenetic traits in the next generation. This work solves a longstanding puzzle of how paternal epigenetic information travels from seminal plasma into mature sperm. In neurobiology, amyloid proteins are commonly known as pathological hallmarks of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease; their aggregated, toxic plaques and fibers disrupt synaptic function. This study demonstrates, however, that functional amyloid proteins carry out essential, nonpathological physiological roles inside the human body.
On October 28, researchers from Harvard Medical School and Boston Children’s Hospital published a paper in Nature. Their work shows that roughly one quarter of fetal neurons carry severe DNA abnormalities, including diverse copy-number variants. These abnormal neurons are selectively eliminated around the time of birth, because their copy-number variants impair synapse formation. This mechanism represents a critical genome quality-control step during brain development, a form of purifying selection in human neurodevelopment. Failures in this process may contribute to neurodevelopmental disorders.
Also on October 28, Danish biotech firm Genmab reported results from the interim analysis of a Phase 3 trial in patients with PD-L1-positive recurrent or metastatic head and neck cancer. The investigational agent, petosemtamab — a fully human IgG1 bispecific antibody targeting tumor cells that express epidermal growth factor receptor and leucine-rich repeat-containing G-protein coupled receptor 5 — demonstrated statistically meaningful and clinically meaningful improvements in overall survival and objective response when combined with pembrolizumab. Compared with pembrolizumab alone, the combination reduced the risk of death by 50 percent, and the likelihood of achieving an objective response was more than three times higher in the combination arm. Treatment benefits were observed regardless of human papillomavirus status. Squamous cell carcinoma accounts for more than 90 percent of all head and neck cancers, arising from the lining of the oral cavity, pharynx and larynx. While multiple treatment options exist, demand for new therapies remains high; approximately half of patients with locally advanced disease experience relapse after initial treatment.
On October 29, a collaborative team from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences, Changhai Hospital, Shanghai General Hospital and Chongqing Medical University published their work in Cancer Cell. Using a large biobank of patient-derived pancreatic cancer organoids together with multi-omic profiling, functional screening and in vivo experiments, the team systematically mapped the molecular features underlying intrinsic resistance to KRAS G12D targeted therapy in pancreatic cancer. They identified interferon signaling activity as an important determinant of treatment sensitivity and further linked elevated MYC activity to suppression of interferon signaling and resistance to KRAS inhibition. The researchers found that interferon beta can resensitize intrinsically resistant pancreatic cancer organoids to KRAS inhibitors. These findings offer a new direction for overcoming resistance to KRAS-targeted therapy and designing rational combination strategies for pancreatic cancer.